Fuji Pharma Co., Ltd. provided financial guidance for the fiscal year ending September 30, 2022. In the current fiscal year, the company plan to increase both sales and profits for the second consecutive year. Net sales are expected to increase due to the new F-meno? Capsules, the newly in-licensed product PROPESS?, existing products in the field of women's healthcare centered 6 key products, and the expected contribution OLIC recovers from results seen during COVID-19 impact. Operating profit is expected to increase due to the increase in net sales, which will offset the increase in R&D and SG&A expenses. Forecasts operating profit increase of 4.2% YoY to JPY 3.5 billion. Operating profit for the fiscal year is expected to increase. This is because the increase in revenue will offset the increase in R&D expenses and expenses due to COVID-19 sedation.